III期随机CLEAR试验的生物标志物分析:仑伐替尼联合帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌
CLEAR试验中仑伐替尼联合帕博利珠单抗(L+P)一线治疗晚期肾细胞癌疗效优于舒尼替尼。本分析对存档肿瘤标本行PD-L1免疫组化及全外显子/RNA测序,结果显示L+P的客观缓解率和PFS获益在RCC驱动基因突变、PD-L1、基因表达特征及分子亚型定义的各生物标志物亚组中一致。
要点
- L+P对比舒尼替尼的PFS获益在RCC驱动基因突变各亚组中一致。
- PD-L1水平与两治疗组的最佳总体缓解或PFS均无关联。
- 分子亚型与L+P或舒尼替尼的PFS均无关联。
核心结论
- L+P对比舒尼替尼在aRCC中客观缓解率和PFS的改善,在RCC驱动基因突变、PD-L1、基因表达特征和分子亚型定义的各生物标志物亚组中一致观察到。
研究设计与样本
- CLEAR为III期随机试验,本报告为其生物标志物分析。
- 对存档肿瘤标本行PD-L1免疫组化及下一代测序(全外显子测序/RNA测序)。
- 免疫组化/RNA测序分析采用连续变量分析并按Karnofsky体能状态评分校正。
- RCC驱动基因突变状态与PFS的关联仅分析每臂≥20例患者有致癌改变的基因。
主要发现
- 组内连续值分析显示两治疗组的PD-L1水平与最佳总体缓解或PFS均无关联。
- RCC驱动基因(VHL、PBRM1、SETD2、BAP1、KDM5C)突变型或野生型亚组间,两组间的PFS风险比相似。
- L+P组未观察到基因特征评分与PFS的关联;舒尼替尼组高增殖和高MYC特征评分显示PFS较短,高血管生成和微血管密度特征评分显示PFS较长。
- 共定义6个新分子亚型; favorable/intermediate风险患者的肿瘤富集于血管生成及血管生成/基质簇,poor风险患者富集于增殖和未分类(低TcellinfGEP/低血管生成/低增殖)簇。
- 按KPS及单独与PFS相关的基因特征校正后,分子亚型与L+P或舒尼替尼的PFS均无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In CLEAR, lenvatinib + pembrolizumab (L + P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (aRCC). We report results from CLEAR biomarker analyses. PATIENTS AND METHODS: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA sequencing) were carried out on archival tumor specimens. For IHC-derived/RNA sequencing analyses, a continuous analysis was carried out adjusting by Karnofsky performance status (KPS) score for: PD-L1 combined positive score (CPS) versus best overall response (BOR)/progression-free survival (PFS); and each gene signature score [T-cell inflamed gene expression profile (TcellinfGEP)/non-TcellinfGEP signatures including proliferation and angiogenesis] versus BOR/PFS. Association between mutation status of RCC driver genes and PFS were analyzed for genes for which ≥20 patients per arm had oncogenic alterations. Association of molecular subtypes with outcome was evaluated with baseline KPS adjustments. The set of biomarkers evaluated and statistical significance criteria for PD-L1 CPS, gene signature scores, and molecular subtypes were prespecified. RESULTS: Within-arm analyses using continuous values showed no association between PD-L1 levels and BOR/PFS for either treatment. PFS hazard ratios between arms were similar regardless of the mutant or wild-type subgroups of RCC driver genes (VHL, PBRM1, SETD2, BAP1, KDM5C). No associations between PFS and gene signature scores were observed for L + P. With sunitinib, high proliferation and MYC signature scores showed shorter PFS; high angiogenesis and microvessel density signature scores showed longer PFS. Six new molecular subtypes were defined. Tumors of patients with favorable/intermediate risk were enriched in angiogenesis and angiogenesis/stromal clusters; those with poor risk were enriched in proliferative and unclassified (low-TcellinfGEP/low-angiogenesis/low-proliferation) clusters. No association between molecular subtypes and PFS for L + P/sunitinib was observed (after adjustment for KPS and gene signatures that were individually associated with PFS). CONCLUSIONS: Improvements in objective response rate and PFS for L + P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and molecular subtypes.
引用
- Motzer RJ, Porta C, Eto M, et al. Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Ann Oncol. 2024. PMID: 39672382. doi:10.1016/j.annonc.2024.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。